Comparative Analysis of Gene Expression in Fibroblastic Foci in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis

Background: Fibroblastic foci (FF) are characteristic features of usual interstitial pneumonia (UIP)/idiopathic pulmonary fibrosis (IPF) and one cardinal feature thought to represent a key mechanism of pathogenesis. Hence, FF have a high impact on UIP/IPF diagnosis in current guidelines. However, although less frequent, these histomorphological hallmarks also occur in other fibrotic pulmonary diseases. Currently, there is therefore a gap in knowledge regarding the underlying molecular similarities and differences of FF in different disease entities. Methods: In this work, we analyzed the compartment-specific gene expression profiles of FF in IPF and sarcoidosis in order to elucidate similarities and differences as well as shared pathomechanisms. For this purpose, we used laser capture microdissection, mRNA and protein expression analysis. Biological pathway analysis was performed using two different gene expression databases. As control samples, we used healthy lung tissue that was donated but not used for lung transplantation. Results: Based on Holm Bonferroni corrected expression data, mRNA expression analysis revealed a significantly altered expression signature for 136 out of 760 genes compared to healthy controls while half of these showed a similar regulation in both groups. Immunostaining of selected markers from each group corroborated these results. However, when comparing all differentially expressed genes with the fdr-based expression data, only 2 of these genes were differentially expressed between sarcoidosis and IPF compared to controls, i.e., calcium transport protein 1 (CAT1) and SMAD specific E3 ubiquitin protein ligase 1 (SMURF1), both in the sarcoidosis group. Direct comparison of sarcoidosis and IPF did not show any differentially regulated genes independent from the statistical methodology. Biological pathway analysis revealed a number of fibrosis-related pathways pronounced in IPF without differences in the regulatory direction. Conclusions: These results demonstrate that FF of end-stage IPF and sarcoidosis lungs, although different in initiation, are similar in gene and protein expression, encouraging further studies on the use of antifibrotic agents in sarcoidosis.

[1]  Hongying Zhao,et al.  Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling , 2020, BMC cancer.

[2]  K. Izuhara,et al.  Plasma matrix metalloproteinase 7, CC-chemokine ligand 18, and periostin as markers for pulmonary sarcoidosis. , 2020, Respiratory investigation.

[3]  Dongfeng Chen,et al.  Src family kinases and pulmonary fibrosis: A review. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  M. Jamal-Hanjani,et al.  Transcriptome analysis of IPF fibroblastic foci identifies key pathways involved in fibrogenesis , 2020, Thorax.

[5]  D. Riches,et al.  Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases , 2019, European Respiratory Journal.

[6]  Wande Li,et al.  LOX/LOXL in pulmonary fibrosis: potential therapeutic targets , 2018, Journal of drug targeting.

[7]  F. Länger,et al.  Schädigungsmuster interstitieller Lungenerkrankungen , 2018, Der Pathologe.

[8]  Takeshi Johkoh,et al.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[9]  E. White,et al.  Correction: Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis (doi: 10.1242/dmm.030114) , 2017, Disease Models & Mechanisms.

[10]  D. Lynch,et al.  Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. , 2017, The Lancet. Respiratory medicine.

[11]  Seidai Sato,et al.  Lysyl Oxidase‐Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor‐&bgr;1‐induced Pulmonary Fibrosis , 2017, American journal of respiratory cell and molecular biology.

[12]  E. White,et al.  Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis , 2017, Disease Models & Mechanisms.

[13]  T. Welte,et al.  Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation , 2016, The journal of pathology. Clinical research.

[14]  S. Benvenuti,et al.  Ockham’s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer , 2016, Journal of Translational Medicine.

[15]  J. Myers,et al.  Histopathology of Explanted Lungs From Patients With a Diagnosis of Pulmonary Sarcoidosis. , 2016, Chest.

[16]  O. Sokhatska,et al.  Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. , 2015, Respiratory medicine.

[17]  G. Rossi,et al.  Pathology of Sarcoidosis , 2015, Clinical Reviews in Allergy & Immunology.

[18]  A. Günther,et al.  The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis , 2015, European Respiratory Journal.

[19]  Alexander Pautsch,et al.  Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis , 2015, European Respiratory Journal.

[20]  Gang Liu,et al.  Therapeutic Targeting of Src Kinase in Myofibroblast Differentiation and Pulmonary Fibrosis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[21]  M. Falasca,et al.  Role of phospholipase C in cell invasion and metastasis. , 2013, Advances in biological regulation.

[22]  J. Distler,et al.  Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. , 2013, Biochimica et biophysica acta.

[23]  H. Iwasaki,et al.  Prognostic significance of fibroblastic foci in usual interstitial pneumonia and non‐specific interstitial pneumonia , 2013, Respirology.

[24]  R. Baughman,et al.  A concise review of pulmonary sarcoidosis. , 2011, American journal of respiratory and critical care medicine.

[25]  Lei Zhou,et al.  [Change of matrix metalloproteinase-1 and matrix metalloproteinase-7 in serum and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and sarcoidosis]. , 2010, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[26]  Naftali Kaminski,et al.  MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis , 2008, PLoS medicine.

[27]  P. Piirilä,et al.  Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[28]  Alok Tomar,et al.  Obligatory role for phospholipase C-γ1 in villin-induced epithelial cell migration , 2007 .

[29]  Ling Zhu,et al.  TGF-β-regulated collagen type I accumulation: role of Src-based signals , 2007 .

[30]  S. Gilpin,et al.  Cell-specific gene expression in patients with usual interstitial pneumonia. , 2006, American journal of respiratory and critical care medicine.

[31]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[32]  Naftali Kaminski,et al.  Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  W. Travis,et al.  Nonspecific interstitial pneumonia (NSIP). , 2001, Seminars in respiratory and critical care medicine.

[34]  J. Myers,et al.  Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. , 1998, American journal of respiratory and critical care medicine.

[35]  A. Churg,et al.  Pathology of Chronic Hypersensitivity Pneumonitis What Is It? What Are the Diagnostic Criteria? Why Do We Care? , 2018, Archives of pathology & laboratory medicine.

[36]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[37]  S. Rosselot Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[38]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[39]  R. Govindarajan,et al.  Pulmonary sarcoidosis. , 1985, The Journal of the Association of Physicians of India.